1. Home
  2. AVTX vs MCHX Comparison

AVTX vs MCHX Comparison

Compare AVTX & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVTX
  • MCHX
  • Stock Information
  • Founded
  • AVTX 2011
  • MCHX 2003
  • Country
  • AVTX United States
  • MCHX United States
  • Employees
  • AVTX N/A
  • MCHX N/A
  • Industry
  • AVTX Biotechnology: Pharmaceutical Preparations
  • MCHX Business Services
  • Sector
  • AVTX Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • AVTX Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • AVTX 88.4M
  • MCHX 84.3M
  • IPO Year
  • AVTX 2015
  • MCHX 2004
  • Fundamental
  • Price
  • AVTX $8.04
  • MCHX $2.02
  • Analyst Decision
  • AVTX Strong Buy
  • MCHX
  • Analyst Count
  • AVTX 4
  • MCHX 0
  • Target Price
  • AVTX $33.00
  • MCHX N/A
  • AVG Volume (30 Days)
  • AVTX 73.8K
  • MCHX 26.2K
  • Earning Date
  • AVTX 03-28-2025
  • MCHX 03-13-2025
  • Dividend Yield
  • AVTX N/A
  • MCHX N/A
  • EPS Growth
  • AVTX N/A
  • MCHX N/A
  • EPS
  • AVTX N/A
  • MCHX N/A
  • Revenue
  • AVTX $820,000.00
  • MCHX $48,594,000.00
  • Revenue This Year
  • AVTX N/A
  • MCHX N/A
  • Revenue Next Year
  • AVTX N/A
  • MCHX $4.63
  • P/E Ratio
  • AVTX N/A
  • MCHX N/A
  • Revenue Growth
  • AVTX N/A
  • MCHX N/A
  • 52 Week Low
  • AVTX $4.17
  • MCHX $1.11
  • 52 Week High
  • AVTX $34.46
  • MCHX $2.40
  • Technical
  • Relative Strength Index (RSI)
  • AVTX 51.97
  • MCHX 55.00
  • Support Level
  • AVTX $7.08
  • MCHX $1.92
  • Resistance Level
  • AVTX $8.44
  • MCHX $2.06
  • Average True Range (ATR)
  • AVTX 0.83
  • MCHX 0.08
  • MACD
  • AVTX 0.20
  • MCHX 0.01
  • Stochastic Oscillator
  • AVTX 83.84
  • MCHX 85.71

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: